Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Investor Presentation (June 2022)
25 slides from Orchid Pharma's investor presentation, June 2022
Slide 1: Investor Presentation – June 2022
(BSE : 524372; NSE: ORCHPHARMA) Investor Presentation – June 2022
Slide 2: Safe Harbor
SAFE HARBOR This presentation and the accompanying slides (the “Presentation”), which have been prepared by Orchid Pharma Ltd (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities,
Slide 3: Company Overview
Company Overview
Slide 4: Company Overview
Company Overview DHANUKA GROUP PIONEER IN CEPHALOSPORIN ANTIBIOTICS ✓ Diversified group with interests in Pharmaceuticals and Crop Care with a • R&D Focused, Inventor of Enmetazobactam – First NCE invented in India. combined Mcap of ~$ 600 Mn & Total Sales of ~$ 325 Mn (Mar’22) • Acquired by Dhanuka
Slide 5: Dhanuka Group acquired Orchid Pharma in 2020
Dhanuka Group acquired Orchid Pharma in 2020 1992 2005 2008 2009 ▪ Orchid was formed ▪ First USFDA Approval ▪ First ANDA Approval ▪ First Para-IV filing for Pip-Taz in ▪ FDF Facility Inaugurated by Dr. APJ ▪ Partnership with Merck for collaboration with Apotex Abdul Kalam Drug Discovery ▪ Sells Inje
Slide 6: Background of Dhanuka Group
Background of Dhanuka Group DHANUKA AGRITECH LTD DHANUKA LABORATORIES LTD • Flagship of the Group founded in 1980 • Pharmaceutical arm started in 1998. • Listed on Stock Exchanges for 35 years • Leader in Cephalosporin Antibiotics with a Market Cap of USD 441mn as on in Emerging markets 31st March’2
Slide 7: Why Orchid Pharma?
Why Orchid Pharma ?
Slide 8: Experienced Board & Management Team
Experienced Board & Management Team Mr. Ram Gopal Agarwal Mr. Manish Dhanuka Mr. Arun Dhanuka Mr. Mridul Dhanuka Chairman and Non-Executive Non-Executive Director Whole-Time Director Managing Director Director Visionary Leader at the helm of Chemical Engineer & MBA; Founder Chairman of Dhanuka Direc
Slide 9: Largest integrated Cephalosporin API company
Largest integrated Cephalosporin API company Orchid Pharma Ltd. among India’s leading pharmaceutical players Vertically integrated with credentials in research, manufacturing and marketing Operations cover the entire pharmaceutical value chain from discovery to delivery Presence across the antibioti
Slide 10: State of the Art Manufacturing with Zero Discharge
State of the Art Manufacturing with Zero Discharge • Integrated facilities from Intermediate to finished – 60 Acre • Sterile – 3 Lines Sterile Crystalline and 1 Lyophilized • Oral – 7 Blocks with multiple lines • Intermediates – 5 Blocks with multiple lines • Total Capacity 1050MT (Current & under d
Slide 11: Widest range of Cephalosporins
Widest range of Cephalosporins GENERATION 6 GENERATION 5 GENERATION 4 GENERATION 3 GENERATION 2 STERILE GENERATION 1 • Cefepime + Enmetazobactam STERILE • Ceftazidime + Avibactam • Ceftaroline STERILE • Ceftobiprole ORAL • Cefepime • Ceftolozane • Cefdinir • Cefpirome ORAL • Cefditoren • Cefquinome
Slide 12: Strong R&D capabilities
Strong R&D capabilities Orchid pharma has been focused on R&D, will continue to invest in it Preparative HPLC TGA ANALYTICAL R&D LCMS/MS NMR (Multinuclear) Powder XRD DSC Several patents granted (or under grant), of more than 900 patents filed internationally; over 350 Ion Chromatograph applications
Slide 13: Global presence with a wide Customer base
Global presence with a wide Customer base Revenue Breakup by Geography (FY-22) 3% 7% 2% Africa 13% 29% Asia Europe North America South America 46% India 13
Slide 14: First product invented in India
First product invented in India ENMETAZOBACTUM • In 2013, Orchid out licensed a NCE Enmetazobactam to Allecra Therapeutics, Germany for Clinical Trials. Cleared the Phase 3 trials in October 2020. • This is a Unique Beta Lactamase Inhibitor, in combination with Cefepime. • Targeted for treating cUTI
Slide 15: The year of turnaround
TheThe year of turnaround
Slide 16: Progress of Turnaround
Progress of Turnaround …..since acquisition Revenues EBITDA Record Revenues of Rs. 178.13 Crs 688 53 in Q4FY22 50 600 560 508 16 450 -18 -25 Record EBITDA of Rs. 24.67 Crs in Q4FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Term Debt Product – Market Mix Term Debt reduced by Rs. 279 Crs 427
Slide 17: Merger of Dhanuka Laboratories with Orchid
Merger of Dhanuka Laboratories with Orchid SYNERGIES OF OPTIMIZATION OF DIVERSIFICATION ALIGNMENT OF MARKET SHARE SCALE CAPACITIES INTO NPNC APIS R&D STRENGTHS GAINS › Common RM › DLL - Ozonation › DMFs of Orchid › Optimal use of › Access to each and Vendors. facility, to be site transferred Researc
Slide 18: Corporate structure post acquisition by Dhanuka Group
Corporate structure post acquisition by Dhanuka Group CURRENT SHAREHOLDING PATTERN POST-SCHEME Dhanuka Public SHAREHOLDING PATTERN OF Group ORCHID PHARMA 70% 30% HOLDING HOLDING Dhanuka Agritech Ltd. (Mcap- Rs. ~ 3,339 Crs) Dhanuka Non- Laboratories Promoter Public Non-Public Dhanuka Laboratories Lt
Slide 19: Quarterly Profit and Loss Statement
Quarterly Profit and Loss Statement Particulars (Rs.Crs ) Q4FY22 Q4FY21 Y-o-Y Q3FY22 Q-o-Q FY22 FY21 Y-o-Y Revenue from Operations 178.1 119.6 49.0% 161.4 10.4% 559.6 450.1 24.3% Cost of Materials consumed 98.8 56.1 81.3 340.6 245.6 Changes in Inventories 3.2 22.2 11.1 -27.1 -17.1 Total Raw Material
Slide 20: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs. Crs.) FY22 FY21 FY20 FY19 FY18 Total Revenue 559.6 450.1 483.8 600.0 687.8 Cost of Material Consumed 340.6 245.6 221.2 262.8 341.4 Change in Inventories of finished goods and Work in progress -27.1 -17.1 -18.3 26.6 7.6 Purchase of stock in trade 0.0 0.0 0.5
Slide 21: Balance sheet – Assets (1/2)
Balance sheet – Assets (1/2) ASSET (Rs. Crs.) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Non ‐ Current Assets Property, plant and equipment 583.4 670.1 843.7 1,140.6 1,268.3 Capital work‐in‐progress 9.8 7.4 15.1 263.8 257.2 Intangible Assets 0.3 0.4 14.2 115.7 117.9 Intangible Assets under development 0.0 0
Slide 22: Balance sheet – Equity & Liabilities (2/2)
Balance sheet – Equity & Liabilities (2/2) EQUITY & LIABILITIES (Rs. Crs.) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity Equity Share Capital 40.8 40.8 40.8 89.0 89.0 Other Equity 606.6 612.1 725.2 -793.0 -880.7 Total Equity 647.4 652.9 766.0 -704.0 -791.8 Liabilities Non ‐ Current Liabilities Financial
Slide 23: Cash Flow Statement
Cash Flow Statement Cash Flow Statement (Rs. Crs.) FY22 FY21 FY20 FY19 FY18 Profit before Tax -2.0 -116.5 -131.1 69.4 -399.0 Adjustment for Non-Operating Items -36.8 -172.2 -139.6 -57.3 -453.5 Operating Profit before Working Capital Changes 33.4 55.6 8.5 126.7 54.5 Changes in Working Capital 59.6 -3
Slide 24: Awards and Accolades
Awards and Accolades 2022 2013 2012 2011 2011 Awarded IGCW – 2011 Green Recognised as a Three Star Received EXIM Achievement Received EXIM Achievement Award Alathur facility was awarded Innovation Award for the Export House by the Ministry of Award 2012 for its meritorious 2012 for its meritorious e
Slide 25: Thank you
Thank you Orchid Pharma Ltd CIN : L24222TN1992PLC022994 Ms. Nikita K- Company Secretary nikitak@orchidpharma.com Mr. Sunil Gupta- Chief Financial Officer sunilgupta@orchidpharma.com Mr. Irfan Raeen +91 97737 78669 irfan.raeen@linkintime.co.in Mr. Ashish Chovatia +91 99300 44680 ashish.chovatia@linki